{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gamunex-C",
    "query": {
      "intervention": "Gamunex-C"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gamunex-C&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T11:16:03.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01828294",
      "title": "Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Subcutaneous immunoglobulins",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 4,
      "start_date": "2011-10",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • St Louis, Missouri",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828294"
    },
    {
      "nct_id": "NCT00419341",
      "title": "Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "Human Normal Immunoglobulin for Subcutaneous Administration",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 49,
      "start_date": "2006-11",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419341"
    },
    {
      "nct_id": "NCT01465958",
      "title": "Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "GAMUNEX-C",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 12,
      "start_date": "2011-11",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-03-13",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Centennial, Colorado • Hollywood, Florida + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465958"
    },
    {
      "nct_id": "NCT01019876",
      "title": "Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bone Marrow Failure",
        "Osteopetrosis",
        "Fanconi Anemia",
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Anti-thymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Horse Anti-thymocyte Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 38,
      "start_date": "2002-09",
      "completion_date": "2021-09-07",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01019876"
    },
    {
      "nct_id": "NCT02915263",
      "title": "The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Complications",
        "Diabetes Mellitus",
        "Diabetic Neuropathies"
      ],
      "interventions": [
        {
          "name": "IGIV-C",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 13,
      "start_date": "2017-09-11",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-07",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915263"
    },
    {
      "nct_id": "NCT02042027",
      "title": "Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization",
        "Corneal Graft Failure",
        "Anterior Segment Inflammation"
      ],
      "interventions": [
        {
          "name": "Gamunex-C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-05",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02042027"
    },
    {
      "nct_id": "NCT03401073",
      "title": "IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Idiopathic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-01",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401073"
    },
    {
      "nct_id": "NCT02027701",
      "title": "Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "IgPro20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2014-07-30",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-02",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Kansas City, Kansas + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027701"
    },
    {
      "nct_id": "NCT00473824",
      "title": "Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sequelae of Viral Hepatitis",
        "Transplantation Infection",
        "Evidence of Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "Hepatitis C Immune Globulin Intravenous (Human) 5%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ADMA Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2007-05",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473824"
    },
    {
      "nct_id": "NCT00025038",
      "title": "Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Juvenile Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "isotretinoin",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "double-unit umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 100,
      "start_date": "2001-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-04-11",
      "last_synced_at": "2026-09-02T11:16:03.243Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025038"
    }
  ]
}